findmyKOL
Clinical trialNCT04323800CompletedPhase 2Interventional

Convalescent Plasma to Stem Coronavirus (CSSC-001)

SponsorJohns Hopkins UniversityEnrollment180ConvalescenceCoronavirus
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

  • Center for American Indian Health - Whiteriver Office

    Whiteriver, Arizona, United States

  • University of California, San Diego

    La Jolla, California, United States

  • University of California, Los Angeles

    Los Angeles, California, United States

  • University of California, Irvine Health

    Orange, California, United States

  • Western Connecticut Health Network, Danbury Hospital

    Danbury, Connecticut, United States

  • Western Connecticut Health Netowrk, Norwalk Hospital

    Norwalk, Connecticut, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, United States

  • University of Miami

    Coral Gables, Florida, United States

  • University of Miami Clinical Translational Research Site

    Miami, Florida, United States

  • Northshore University Healthsystem

    Evanston, Illinois, United States

  • Anne Arundel Medical Center

    Annapolis, Maryland, United States

  • the Johns Hopkins University

    Baltimore, Maryland, United States

  • University of Massachusetts Worcester

    Worcester, Massachusetts, United States

  • Wayne State University

    Detroit, Michigan, United States

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico, United States

  • Center for American Indian Health - Gallup Office

    Gallup, New Mexico, United States

  • Center for American Indian Health - Shiprock Office

    Shiprock, New Mexico, United States

  • Vassar Brothers Medical Center

    Poughkeepsie, New York, United States

  • University of Rochester

    Rochester, New York, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, United States

  • Lifespan/brownuniversity (rhode Island Hospital)

    Providence, Rhode Island, United States

  • Baylor College of Medicine

    Houston, Texas, United States

  • University of Texas Health Science Center at Houston

    Houston, Texas, United States

  • the University of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti- SARS-CoV-2 PlasmaSARS-CoV-2 non-immune Plasma
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Jun 2020
Primary completion
22 Apr 2021
Completion
22 Jun 2021
Last update posted
26 Apr 2022
Registered enrollment
180
Registry id
NCT04323800

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.